title: Increased survival by feeding tetradecylthioacetic acid during a natural outbreak of heart and skeletal muscle inflammation in S0 Atlantic salmon, Salmo salar L.
abstract: We have previously documented increased survival by feeding tetradecylthioacetic acid (TTA) during a natural outbreak of infectious pancreatic necrosis in post-smolt S1 Atlantic salmon. The aim of the present study was to test the effects of dietary TTA in S0 smolt at a location where fish often experience natural outbreaks of heart and skeletal muscle inflammation (HSMI) during their first spring at sea. The experimental groups were fed a diet supplemented with 0.25% TTA for a 6-week period prior to a natural outbreak of HSMI in May 2007. Relative percent survival for the groups fed TTA was 45% compared with control diets, reducing mortality from 4.7% to 2.5%. Expression of genes related to lipid oxidation was higher in cardiac ventricles from salmon fed TTA compared with controls. In addition, salmon fed TTA had periodically reduced levels of plasma urea, and increased cardiosomatic index and growth. Reduced mortality and increased growth after administration of TTA may be related to a combination of anti-inflammatory effects, and an altered metabolic balance with better protein conservation because of increased lipid degradation.
authors: NOFIMA, As, Norway.
authors: H
authors: H
authors: Alne
authors: M S
authors: MS
authors: Thomassen
authors: H
authors: H
authors: Takle
authors: B F
authors: BF
authors: Terjesen
authors: F
authors: F
authors: Grammes
authors: M
authors: M
authors: Oehme
authors: S
authors: S
authors: Refstie
authors: T
authors: T
authors: Sigholt
authors: R K
authors: RK
authors: Berge
authors: K-A
authors: KA
authors: Rørvik
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D005227:Fatty Acids / Q000627:therapeutic use*; D005393:Fish Diseases / Q000188:drug therapy* / Q000401:mortality; D005786:Gene Expression Regulation / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects; D018482:Muscle, Skeletal / Q000187:drug effects / Q000473:pathology; D009205:Myocarditis / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D009206:Myocardium / Q000473:pathology; D009220:Myositis / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D011897:Random Allocation; D020317:Salmo salar / Q000502:physiology*; D013440:Sulfides / Q000494:pharmacology / Q000627:therapeutic use*; D016019:Survival Analysis; D014508:Urea / Q000097:blood
chemical_list: D005227:Fatty Acids; D013440:Sulfides; C062078:1-(carboxymethylthio)tetradecane; D014508:Urea